Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 5/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.33 |
| ▸ | PDE5A | O76074 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588237 | 0.94 | PDE9A (0.41) | PDE9APARP1FFAR1PDE5AMEN1 | |
| SCHEMBL3591562 | 0.92 | PDE9A (0.43) | PDE9APARP1FFAR1PDE5AMEN1 | |
| SCHEMBL3592942 | 0.88 | PDE9A (0.42) | PDE9APARP1FFAR1PDE5AMEN1 | |
| SCHEMBL18098752 | 0.79 | PDE9A (0.38) | PDE9APARP1PDE5A | |
| SCHEMBL3592747 | 0.78 | PDE9A (0.51) | PDE9AFFAR1PDE5A | |
| SCHEMBL3596910 | 0.76 | PDE9A (0.56) | PDE9APDE5AMEN1KMT2AGRIA1 | |
| SCHEMBL3593625 | 0.75 | PDE9A (0.54) | PDE9AFFAR1PDE5AMEN1KMT2A | |
| SCHEMBL3589459 | 0.73 | PDE9A (0.50) | PDE9AFFAR1PDE5AGRIA1GRIA2 | |
| SCHEMBL3595834 | 0.71 | PDE9A (0.69) | PDE9APARP1FFAR1PDE5AGRIA1 | |
| SCHEMBL3593097 | 0.70 | PDE9A (0.53) | PDE9APARP1FFAR1PDE5AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2848620-B1 | QUINOXALINE DERIVATIVES | ASKA PHARM CO LTD (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040536-B2 | Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2848620-A1 | Quinoxaline derivatives | ASKA Pharmaceutical Co., Ltd. (JP) | 2015-03-18 | — | — | EP | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | ASKA PHARM CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829000-B2 | Substituted imidazo[1,5-A]quinoxalines as phosphodiesterase 9 inhibitors | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8299080-B2 | Substituted imidazo[1,5-A] quinoxalines as a PDE9 inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| EP-2489667-A1 | Quinoxaline derivative | ASKA Pharmaceutical Co., Ltd. (JP) | 2012-08-22 | — | — | EP | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2103613-A1 | QUINOXALINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048556-A1 | QUINOXALINE DERIVATIVES | PDE9A, ADCY9, PRMT9 | PDE9A 1/4885PARP1 3374/4885FFAR1 934/4885 |
| US-20140336197-A1 | SUBSTITUTED IMIDAZO [1,5-a]QUINOXALINES AS A PDE9 INHIBITOR | PDE9A, ADCY9, PDE3A | PDE9A 1/4885PARP1 3075/4885FFAR1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.